Morgan Stanley’s NEVRO CORP. NVRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-579,455
| Closed | -$3.38M | – | 8377 |
|
|
2025
Q1 | $3.38M | Sell |
579,455
-459,851
| -44% | -$2.42M | ﹤0.01% | 4242 |
|
|
2024
Q4 | $3.87M | Buy |
1,039,306
+2,047
| +0.2% | +$9.45K | ﹤0.01% | 4208 |
|
|
2024
Q3 | $5.8M | Buy |
1,037,259
+699,495
| +207% | +$4.89M | ﹤0.01% | 3860 |
|
|
2024
Q2 | $2.84M | Sell |
337,764
-341,006
| -50% | -$3.64M | ﹤0.01% | 4327 |
|
|
2024
Q1 | $9.8M | Sell |
678,770
-340,562
| -33% | -$5.63M | ﹤0.01% | 3363 |
|
|
2023
Q4 | $21.9M | Buy |
1,019,332
+705,646
| +225% | +$12.6M | ﹤0.01% | 3247 |
|
|
2023
Q3 | $6.03M | Sell |
313,686
-86,319
| -22% | -$1.84M | ﹤0.01% | 3585 |
|
|
2023
Q2 | $10.2M | Sell |
400,005
-18,674
| -4% | -$539K | ﹤0.01% | 3145 |
|
|
2023
Q1 | $15.1M | Sell |
418,679
-125,339
| -23% | -$4.4M | ﹤0.01% | 2720 |
|
|
2022
Q4 | $21.5M | Buy |
544,018
+111,947
| +26% | +$4.66M | ﹤0.01% | 2261 |
|
|
2022
Q3 | $20.1M | Sell |
432,071
-67,696
| -14% | -$3.14M | ﹤0.01% | 2183 |
|
|
2022
Q2 | $21.9M | Sell |
499,767
-1,675
| -0.3% | -$92.1K | ﹤0.01% | 2183 |
|
|
2022
Q1 | $36.3M | Buy |
501,442
+145,743
| +41% | +$10.5M | ﹤0.01% | 1536 |
|
|
2021
Q4 | $28.8M | Buy |
355,699
+51,262
| +17% | +$5.14M | ﹤0.01% | 1781 |
|
|
2021
Q3 | $35.4M | Sell |
304,437
-79,684
| -21% | -$10.4M | ﹤0.01% | 1543 |
|
|
2021
Q2 | $63.7M | Sell |
384,121
-238,458
| -38% | -$37.2M | 0.01% | 1144 |
|
|
2021
Q1 | $86.8M | Buy |
622,579
+211,332
| +51% | +$34.5M | 0.01% | 834 |
|
|
2020
Q4 | $71.2M | Buy |
411,247
+43,542
| +12% | +$7.05M | 0.01% | 884 |
|
|
2020
Q3 | $51.2M | Sell |
367,705
-29,578
| -7% | -$3.95M | 0.01% | 885 |
|
|
2020
Q2 | $47.5M | Buy |
397,283
+184,015
| +86% | +$21.8M | 0.01% | 864 |
|
|
2020
Q1 | $21.3M | Sell |
213,268
-12,438
| -6% | -$1.5M | 0.01% | 1235 |
|
|
2019
Q4 | $26.5M | Buy |
225,706
+31,371
| +16% | +$3.11M | 0.01% | 1412 |
|
|
2019
Q3 | $16.7M | Buy |
194,335
+39,423
| +25% | +$2.98M | ﹤0.01% | 1636 |
|
|
2019
Q2 | $10M | Sell |
154,912
-2,041
| -1% | -$127K | ﹤0.01% | 2158 |
|
|
2019
Q1 | $9.81M | Buy |
156,953
+8,163
| +5% | +$384K | ﹤0.01% | 2061 |
|
|
2018
Q4 | $5.79M | Sell |
148,790
-83,403
| -36% | -$3.71M | ﹤0.01% | 2722 |
|
|
2018
Q3 | $13.2M | Sell |
232,193
-34,996
| -13% | -$2.19M | ﹤0.01% | 2116 |
|
|
2018
Q2 | $21.3M | Sell |
267,189
-3,399
| -1% | -$282K | 0.01% | 1582 |
|
|
2018
Q1 | $23.5M | Sell |
270,588
-7,555
| -3% | -$610K | 0.01% | 1525 |
|
|
2017
Q4 | $19.2M | Buy |
278,143
+42,636
| +18% | +$3.41M | 0.01% | 1704 |
|
|
2017
Q3 | $21.4M | Sell |
235,507
-4,139
| -2% | -$354K | 0.01% | 1524 |
|
|
2017
Q2 | $17.8M | Sell |
239,646
-49,861
| -17% | -$3.99M | 0.01% | 1634 |
|
|
2017
Q1 | $27.1M | Sell |
289,507
-24,933
| -8% | -$2.26M | 0.01% | 1318 |
|
|
2016
Q4 | $22.8M | Buy |
314,440
+67,241
| +27% | +$5.76M | 0.01% | 1415 |
|
|
2016
Q3 | $25.8M | Buy |
247,199
+128,117
| +108% | +$11.6M | 0.01% | 1272 |
|
|
2016
Q2 | $8.78M | Buy |
119,082
+41,196
| +53% | +$2.8M | ﹤0.01% | 2097 |
|
|
2016
Q1 | $4.38M | Buy |
77,886
+1,741
| +2% | +$103K | ﹤0.01% | 2664 |
|
|
2015
Q4 | $5.14M | Sell |
76,145
-22,284
| -23% | -$1.19M | ﹤0.01% | 2640 |
|
|
2015
Q3 | $4.57M | Sell |
98,429
-35,534
| -27% | -$1.72M | ﹤0.01% | 2736 |
|
|
2015
Q2 | $7.2M | Buy |
133,963
+71,684
| +115% | +$3.65M | ﹤0.01% | 2445 |
|
|
2015
Q1 | $2.98M | Sell |
62,279
-33,849
| -35% | -$1.47M | ﹤0.01% | 3205 |
|
|
2014
Q4 | $3.72M | Buy |
+96,128
| New | +$3.03M | ﹤0.01% | 3004 |
|
Other funds holding NVRO
Morgan Stanley's NVRO Position: Q2 2025 in Review
Morgan Stanley sold out of NEVRO CORP. (NVRO) in Q2 2025, closing a stake of 579,455 shares — an estimated $3.38M sold.
Morgan Stanley first reported a position in NVRO in Q4 2014 and held it in 42 quarters. The position peaked at $86.8M in Q1 2021. 1 fund tracked by Wall St. Rank holds NVRO as of Q2 2025.
- Morgan Stanley reported no remaining NEVRO CORP. position as of Q2 2025 after selling out during the quarter.
- Morgan Stanley sold 579,455 NEVRO CORP. shares in Q2 2025, an estimated $3.38M.
- Morgan Stanley first reported a position in NEVRO CORP. in Q4 2014 and held it in 42 quarters.
- Morgan Stanley's NEVRO CORP. position peaked at $86.8M in Q1 2021.
- 1 fund tracked by Wall St. Rank held NEVRO CORP. as of Q2 2025.
Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.